Castle Biosciences CEO Derek Maetzold Sells 43,019 Shares at $19.5/Share

Castle Biosciences Inc., CSTL, has recently announced that Derek J. Maetzold, Director, President, and Chief Executive Officer, has sold 43,019 shares at a price of $19.5 per share on August 13, 2025.

Castle Biosciences Inc. (CSTL) has seen a notable development in its executive shareholding. Derek J. Maetzold, the President & Chief Executive Officer and Director at the company, sold 43,019 shares of Common Stock on August 13, 2025, at a weighted average price of $19.504 per share, totaling $839,042 [1]. This transaction was executed under a Rule 10b5-1 plan adopted on November 11, 2024, as per the SEC Form 4 filing [2].

Following the sale, Maetzold directly owns 69,683 shares and indirectly owns 261,372 shares through various trusts. The sale was part of a broader strategy to manage his equity positions in compliance with SEC regulations.

This development comes amidst Castle Biosciences' recent earnings reports, which have shown mixed results. The company has been navigating revenue challenges, but has also seen positive growth in certain quarters. The latest earnings call highlighted the company's efforts to navigate these challenges and maintain its market position [3].

Investors should monitor this transaction closely, as it may indicate shifts in executive sentiment or strategy. However, it is essential to consider the broader context of Castle Biosciences' financial performance and market position before making any investment decisions.

References:

[1] https://www.tradingview.com/news/tradingview:2cf6a17818acc:0-castle-biosciences-ceo-derek-j-maetzold-sells-shares/
[2] https://www.stocktitan.net/sec-filings/CSTL/form-4-castle-biosciences-inc-insider-trading-activity-fa5dc24d4820.html
[3] https://finance.yahoo.com/quote/CSTL/latest-news/